Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07783802 Clazakizumab Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07783802 clinical trial report covering Clazakizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07783581 Pembrolizumab Squamous cell carcinoma of the oral cavity recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07783581 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07784582 Estradiol Valerate Turner Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07784582 clinical trial report covering Estradiol Valerate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07785128 Mycophenolate Mofetil Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07785128 clinical trial report covering Mycophenolate Mofetil, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07785609 Epinephrine Bitartrate Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07785609 clinical trial report covering Epinephrine Bitartrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07785063 LP-003 (Longbio Pharma) Peanut Hypersensitivity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07785063 clinical trial report covering LP-003 (Longbio Pharma), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07786051 Dexamethasone Sodium Phosphate ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07786051 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07783555 Varenicline Tartrate Marijuana Abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07783555 clinical trial report covering Varenicline Tartrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07783594 Epcoritamab Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07783594 clinical trial report covering Epcoritamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600130938 Lesigercept Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600130938 clinical trial report covering Lesigercept, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07786766 Pemigatinib FGFR2 fusion or rearranged Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07786766 clinical trial report covering Pemigatinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07787429 Mifamurtide Osteosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07787429 clinical trial report covering Mifamurtide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.